Publikationen
2012
Blankenstein T; Coulie PG; Gilboa E; Jaffee EM
The determinants of tumour immunogenicity
Nature Reviews Cancer 12 (4): 307-313 (2012-03-01)
2011
Popovic J; Li LP; Kloetzel PM; Leisegang M; Uckert W; Blankenstein T
The only proposed T-cell epitope derived from the TEL-AML1 translocation is not naturally processed
Blood 118 (4): 946-954 (2011-07-28)
Anders K; Buschow C; Herrmann A; Milojkovic A; Loddenkemper C; Kammertoens T; Daniel P; Yu H; Charo J; Blankenstein T
Oncogene-targeting T cells reject large tumors while oncogene inactivation selects escape variants in mouse models of cancer
Cancer Cell 20 (6): 755-767 (2011-12-13)
2010
Czeh M; Loddenkemper C; Shalapour S; Schoen C; Robine S; Goldscheid E; Stein H; Schueler T; Willimsky G; Blankenstein T
The immune response to sporadic colorectal cancer in a novel mouse model
Oncogene 29 (50): 6591-6602 (2010-12-16)
Hayashida N; Fujimoto M; Tan K; Prakasam R; Shinkawa T; Li L; Ichikawa H; Takii R; Nakai A
Heat shock factor 1 ameliorates proteotoxicity in cooperation with the transcription factor NFAT
EMBO Journal 29 (20): 3459-3469 (2010-10-20)
Li LP; Lampert JC; Chen X; Leitao C; Popovic J; Mueller W; Blankenstein T
Transgenic mice with a diverse human T cell antigen receptor repertoire
Nature Medicine 16 (9): 1029-1034 (2010-09)
Leisegang M; Turqueti-Neves A; Engels B; Blankenstein T; Schendel DJ; Uckert W; Noessner E
T-cell receptor gene-modified T cells with shared renal cell carcinoma specificity for adoptive T-cell therapy
Clinical Cancer Research 16 (8): 2333-2343 (2010-04-15)
2009
Babaylova E; Graifer D; Malygin A; Stahl J; Shatsky I; Karpova G
Positioning of subdomain IIId and apical loop of domain II of the hepatitis C IRES on the human 40S ribosome
Nucleic Acids Research 37 (4): 1141-1151 (2009-03)
Wolf SA; Steiner B; Wengner AM; Lipp M; Kammertoens T; Kempermann G
Adaptive peripheral immune response increases proliferation of neural precursor cells in the adult hippocampus
FASEB Journal 23 (9): 3121-3128 (2009-09)
2008
Kruschinski A; Moosmann A; Poschke I; Norell H; Chmielewski M; Seliger B; Kiessling R; Blankenstein T; Abken H; Charo J
Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas
Proceedings of the National Academy of Sciences of the United States of America 105 (45): 17481-17486 (2008-11-11)
Kieback E; Charo J; Sommermeyer D; Blankenstein T; Uckert W
A safeguard eliminates T cell receptor gene-modified autoreactive T cells after adoptive transfer
Proceedings of the National Academy of Sciences of the United States of America 105 (2): 623-628 (2008-01-15)
Willimsky G; Czeh M; Loddenkemper C; Gellermann J; Schmidt K; Wust P; Stein H; Blankenstein T
Immunogenicity of premalignant lesions is the primary cause of general cytotoxic T lymphocyte unresponsiveness
Journal of Experimental Medicine 205 (7): 1687-1700 (2008-07-07)
2007
Blankenstein T
Do autochthonous tumors interfere with effector T cell responses?
Seminars in Cancer Biology 17 (4): 267-274 (2007-08)
Varga G; Balkow S; Wild MK; Stadtbaeumer A; Krummen M; Rothoeft T; Higuchi T; Beissert S; Wethmar K; Scharffetter-Kochanek K; Vestweber D; Grabbe S
Active MAC-1 (CD11b/CD18) on DC is inhibitory for full T cell activation
Blood 109: 661-669 (2007-01-15)
Willimsky G; Blankenstein T
The adaptive immune response to sporadic cancer
Immunological Reviews 220 (1): 102-112 (2007-12)
Nassenstein C; Kammertoens T; Veres TZ; Uckert W; Spies E; Fuchs B; Krug N; Braun A
Neuroimmune crosstalk in asthma: Dual role of the neurotrophin receptor p75NTR
Journal of Allergy and Clinical Immunology 120(5): 1089-1096 (2007-08-21)
Cayeux S; Bukarica B; Buschow C; Charo J; Bunse M; Doerken B; Blankenstein T
In vivo splenic CD11c cells downregulate CD4 T-cell response thereby decreasing systemic immunity to gene-modified tumour cell vaccine
Gene Therapy 14 (20): 1481-1491 (2007-10)
2005
Kammertoens T; Willebrand R; Erdmann B; Li L; Li Y; Engels B; Uckert W; Blankenstein T
CY15, a malignant histiocytic tumor that is phenotypically similar to immature dendritic cells
Cancer Research 65: 2560-2564 (2005-01-01)
Blankenstein T
The role of tumor stroma in the interaction between tumor and immune system
Current Opinion in Immunology 17: 180-186 (2005-01-01)
Willimsky G; Blankenstein T
Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance
Nature 437: 141-146 (2005-09-01)
2004
Stelljes M; Strothotte R; Pauels HG; Poremba C; Milse M; Specht C; Albring J; Bisping G; Scheffold C; Kammertoens T; Oelmann E; Silling G; Berdel WE; Kienast J
Graft-versus-host disease after allogeneic hematopoietic stem cell transplantation induces a CD8+ T cell-mediated graft-versus-tumor effect that is independent of the recognition of alloantigenic tumor targets
Blood 104: 1210-1216 (2004-01-01)
Ohl L; Mohaupt M; Czeloth N; Hintzen G; Kiafard Z; Zwirner J; Blankenstein T; Henning G; Foerster R
CCR7 governs skin dendritic cell migration under inflammatory and steady-state conditions
Immunity 21 (2): 279-288 (2004-08-01)
Qin ZH; Blankenstein T
A cancer immunosurveillance controversy
Nature Immunology 5: 3-4 (2004-01-01)
2003
Schueler T; Koernig S; Blankenstein T
Tumor rejection by modulation of tumor stromal fibroblasts
Journal of Experimental Medicine 198 (10): 1487-1493 (2003-11-17)
Qin ZH; Schwartzkopff J; Pradera F; Kammertoens T; Seliger B; Pircher H; Blankenstein T
A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8T cells
Cancer Research 63: 4095-4100 (2003-01-01)
Aicher A; Heeschen C; Mohaupt M; Cooke JP; Zeiher AM; Dimmeler S
Nicotine strongly activates dendritic cell-mediated adaptive immunity - Potential role for progression of atherosclerotic lesions
Circulation 107: 604-611 (2003-01-01)
Blankenstein T; Qin ZH
The role of IFN-gamma in tumor transplantation immunity and inhibition of chemical carcinogenesis
Current Opinion in Immunology 15: 148-154 (2003-01-01)
Blankenstein T; Qin Z
Chemical carcinogens as foreign bodies and some pitfalls regarding cancer immune surveillance
Advances in Cancer Research 90: 179-207 (2003-01-01)
2002
Qin ZH; Harders C; Cao XT; Huber C; Blankenstein T; Seliger B
Increased tumorigenicity, but unchanged immunogenicity, of transporter for antigen presentation 1-deficient tumors
Cancer Research 62 (10): 2856-2860 (2002-01-01)
Qin ZH; Kim HJ; Hemme J; Blankenstein T
Inhibition of methylcholanthrene-induced carcinogenesis by an interferon gamma receptor-dependent foreign body reaction
Journal of Experimental Medicine 195 (11): 1479-1490 (2002-06-03)
Blankenstein T; Schueler T
Cross-priming versus cross-tolerance: are two signals enough?
Trends in Immunology 23 (4): 171-173 (2002-01-01)
2001
Schueler T; Kammertoens T; Preiss S; Debs P; Noben-Trauth N; Blankenstein T
Generation of tumor-associated cytotoxic T lymphocytes requires interleukin 4 from CD8+ T cells
Journal of Experimental Medicine 194 (12): 1767-1775 (2001-12-17)
Becker C; Pohla H; Frankenberger B; Schueler T; Assenmacher M; Schendel DJ; Blankenstein T
Adoptive tumor therapy with T lymphocytes enriched through an IFN-gamma capture assay
Nature Medicine 7: 1159-1162 (2001-01-01)
Cayeux S; Qin ZH; Doerken B; Blankenstein T
Decreased generation of anti-tumor immunity after intrasplenic immunization
European Journal of Immunology 31: 1392-1399 (2001-01-01)
Seliger B; Wollscheid U; Momburg F; Blankenstein T; Huber C
Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells
Cancer Research 61: 1095-1099 (2001-01-01)
Michelsen KS; Aicher A; Mohaupt M; Hartung T; Dimmeler S; Kirschning CJ; Schumann RR
The role of toll-like receptors (TLRs) in bacteria-induced maturation of murine dendritic cells (DCS). Peptidoglycan and lipoteichoic acid are inducers of DC maturation and require TLR2
Journal of Biological Chemistry 276: 25680-25686 (2001-07-13)
Ibe S; Qin ZH; Schueler T; Preiss S; Blankenstein T
Tumor rejection by disturbing tumor stroma cell interactions
Journal of Experimental Medicine 194 (11): 1549-1559 (2001-12-03)
Yun TJ; Tallquist MD; Aicher A; Rafferty KL; Marshall AJ; Moon JJ; Ewings MK; Mohaupt M; Herring SW; Clark EA
Osteoprotegerin, a crucial regulator of bone metabolism, also regulates B cell development and function
Journal of Immunology 166: 1482-1491 (2001-01-01)
2000
Willimsky G; Blankenstein T
Interleukin-7/B7.1-encoding adenoviruses induce rejection of transplanted but not nontransplanted tumors
Cancer Research 60: 685-692 (2000-02-01)
Qin ZH; Blankenstein T
CD4+ T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFNgamma receptor expression by nonhematopoietic cells
Immunity 12: 677-686 (2000-06-01)
Schendel DJ; Frankenberger B; Jantzer P; Cayeux S; Noessner E; Willimsky G; Maget B; Pohla H; Blankenstein T
Expression of B7.1 (CD80) in a renal cell carcinoma line allows expansion of tumor-associated cytotoxic T lymphocytes in the presence of an alloresponse
Gene Therapy 7: 2007-2014 (2000-12-01)
Beltinger C; Fulda S; Kammertoens T; Uckert W; Debatin KM
Mitochondrial amplification of death signals determines thymidine kinase/ ganciclovir-triggered activation of apoptosis
Cancer Research 60: 3212-3217 (2000-01-01)
1999
Cayeux S; Richter G; Becker C; Pezzutto A; Doerken B; Blankenstein T
Direct and indirect T cell priming by dendritic cell vaccines
European Journal of Immunology 29: 225-234 (1999-01-01)
Beltinger C; Fulda S; Kammertoens T; Meyer E; Uckert W; Debatin KM
Herpes simplex virus thymidine kinase/ganciclovir-induced apoptosis involves ligand-independent death receptor aggregation and activation of caspases
Proceedings of the National Academy of Sciences of the United States of America 96: 8699-8704 (1999-07-20)
Cayeux S; Qin Z; Doerken B; Blankenstein T
Vaccines using gene-modified tumor cells
Gene therapy :Principles and Applications : 283-298 (1999-01-01)
Schueler T; Qin Z; Ibe S; Noben-Trauth N; Blankenstein T
T helper cell type 1-associated and cytotoxic T lymphocyte-mediated tumor immunity is impaired in interleukin 4-deficient mice
Journal of Experimental Medicine 189 (5): 803-810 (1999-03-01)
1998
Petersson M; Charo J; Salazar-Onfray F; Noffz G; Mohaupt M; Qin ZH; Klein G; Blankenstein T; Kiessling R
Constitutive IL-10 production accounts for the high NK sensitivity, low MHC class I expression, and poor transporter associated with antigen processing (TAP)-1/2 function in the prototype NK target YAC-11
Journal of Immunology 161: 2099-2105 (1998-09-01)
Westermann J; Aicher A; Qin Z; Cayeux S; Daemen K; Blankenstein T; Doerken B; Pezzutto A
Retroviral interleukin-7 gene transfer into human dendritic cells enhances T cell activation
Gene Therapy 5: 264-271 (1998-01-01)
Qin ZH; Richter G; Schueler T; Ibe S; Cao XT; Blankenstein T
B cells inhibit induction of T cell-dependent tumor immunity
Nature Medicine 4: 627-630 (1998-01-01)
Daniel PT; Kroidl A; Cayeux S; Scholz C; Sturm I; Blankenstein T; Pezzutto A; Doerken B
Retroviral B7.1 gene transfer in cancer cells protects cytotoxic T cells from deletion by "veto" apoptosis
Advances in Experimental Medicine and Biology 451: 265-276 (1998-01-01)
Lange C; Schueler T; Blankenstein T
Interleukin 4 gene-defective mice reconstituted with wild-type bone marrow fail to produce normal immunoglobulin E levels
Journal of Experimental Medicine 187 (9): 1487-1493 (1998-05-04)
Noffz G; Qin ZH; Kopf M; Blankenstein T
Neutrophils but not eosinophils are involved in growth suppression of IL-4-secreting tumors
Journal of Immunology 160: 345-350 (1998-01-01)
Jung D; Jaeger E; Cayeux S; Blankenstein T; Hilmes C; Karbach J; Moebius U; Knuth A; Huber C; Seliger B
Strong immunogenic potential of a B7 retroviral expression vector: Generation of HLA-B7-restricted CTL response against selectable marker genes
Human Gene Therapy 9: 53-62 (1998-01-01)
1997
Aicher A; Westermann J; Cayeux S; Willimsky G; Daemen K; Blankenstein T; Uckert W; Doerken B; Pezzutto A
Successful retroviral mediated transduction of a receptor gene in human dendritic cells: feasibility of therapy with gene-modified antigen presenting cells
Experimental Hematology 25: 39-44 (1997-01-01)
Cayeux S; Richter G; Becker C; Beck C; Aicher A; Pezzutto A; Doerken B; Blankenstein T
Lack of correlation between rejection of tumor cells co-expressing interleukin 2 and B7.1 and vaccine efficiency
European Journal of Immunology 27: 1657-1662 (1997-01-01)
Cayeux S; Richter G; Noffz G; Doerken B; Blankenstein T
Influence of gene modified (IL 7, IL 4, and B7) tumor cell vaccines on tumor antigen presentation
Journal of Immunology 158: 2834-2841 (1997-01-01)
Cayeux S; Doerken B; Blankenstein T
Tumor cell vaccines using genetically modified cells coexpressing cytokines and the T cell costimulatory molecule B7
Concepts in Gene Therapy : 487-503 (1997-01-01)
Daniel PT; Kroidl A; Cayeux S; Bargou RC; Blankenstein T; Doerken B
Costimulatory signals through B7.1/CD28 prevent T cell apoptosis during target cell lysis
Journal of Immunology 159 (8): 3808-3815 (1997-10-15)
1996
Cayeux S; Beck C; Doerken B; Blankenstein T
Coexpression of interleukin-4 and B7.1 in murine tumor cells leads to improved tumor rejection and vaccine effect compared to single gene transfectants and a classical adjuvant
Human Gene Therapy 7 (4): 525-529 (1996-01-01)
Brocke S; Gijbels K; Allegretta M; Ferber I; Piercy C; Blankenstein T; Martin R; Utz U; Karin N; Mitchell D; Veromaa T; Waisman A; Gaur A; Conlon P; Ling N; Fairchild PJ; Wraith DC; Ogarra A; Fathman CG; Steinman L
Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein
Nature 379 (6563): 343-346 (1996-01-01)
Blankenstein T; Cayeux S; Qin Z
Genetic approaches to cancer immunotherapy
Reviews of Physiology Biochemistry and Pharmacology 129: 1-49 (1996-01-01)
Blankenstein T; Qin Z
Cancer vaccines in gene therapy
Gene Therapy 3 (2): 95-96 (1996-01-01)
1995
Salazar-Onfray F; Petersson M; Franksson L; Matsuda M; Blankenstein T; Karre K; Kiessling R
IL-10 converts mouse lymphoma cells to a CTL-resistant, nk-sensitive phenotype with low but peptide-inducible MHC class I expression
Journal of Immunology 154 (12): 6291-6298 (1995-01-01)
Qin Z; Blankenstein T
Tumor growth inhibition mediated by lymphotoxin: evidence of B lymphocyte involvement in the antitumor response
Cancer Research 55 (21): 4747-4751 (1995-01-01)
Beck C; Cayeux S; Lupton S; Doerken B; Blankenstein T
The thymidine kinase/ganciclovir-mediated "suicide" effect is highly variable in different tumor cells
Human Gene Therapy 6 (12): 1525-1530 (1995-01-01)
Qin Z; van Tits LJH; Buurman WA; Blankenstein T
Human lymphotoxin has at least equal antitumor activity in comparison to human tumor necrosis factor but is less toxic in mice
Blood 85: 2779-2785 (1995-01-01)
Cayeux S; Beck C; Aicher A; Doerken B; Blankenstein T
Tumor cells cotransfected with interleukin-7 and B7.1 genes induce CD25 and CD28 on tumor-infiltrating T lymphocytes and are strong vaccines
European Journal of Immunology 25 (8): 2325-2331 (1995-01-01)
1993
Hock H; Dorsch M; Kunzendorf U; Qin Z; Diamantstein T; Blankenstein T
Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon-gamma
Proceedings of the National Academy of Sciences of the United States of America 90 (7): 2774-2778 (1993-04-01)
Qin Z; Krueger-Krasagakes S; Kunzendorf U; Hock H; Diamantstein T; Blankenstein T
Expression of tumor necrosis factor by different tumor cell lines results either in tumor suppression or augmented metastasis
Journal of Experimental Medicine 178 (1): 355-360 (1993-07-01)